EirGenix Signs Exclusive License Agreement for Biosimilar EG1206A with Sandoz EirGenix has secured a global exclusive license deal with Sandoz for its HER2 biosimilar EG1206A, marking a significant milestone in oncology.

EirGenix Signs Exclusive License Agreement for Biosimilar EG1206A with Sandoz #Taiwan #Taipei #Sandoz #EirGenix #EG1206A

HER2陽性乳がん治療に新たな選択肢、EirGenixとSandozが提携 EirGenixがSandozと提携し、HER2陽性乳がん用バイオシミラーの商業化契約を締結。治療の選択肢が広がる。

HER2陽性乳がん治療に新たな選択肢、EirGenixとSandozが提携 #EirGenix #Sandoz #HER2陽性乳がん

EirGenixがSandozと提携し、HER2陽性乳がん用バイオシミラーの商業化契約を締結。治療の選択肢が広がる。

EirGenix and Sandoz Join Forces for HER2 Biosimilar Development EirGenix has signed a second exclusive licensing deal with Sandoz for the HER2 biosimilar EG1206A, expanding their collaboration in oncology treatment.

EirGenix and Sandoz Join Forces for HER2 Biosimilar Development #Taiwan #Taipei #Sandoz #HER2 #EirGenix

EirGenix Strengthens Global Presence with New Biosimilar HER2 Licensing Agreement EirGenix secures a global exclusive licensing agreement for biosimilar EG1206A, enhancing cancer treatment options and market presence.

EirGenix Strengthens Global Presence with New Biosimilar HER2 Licensing Agreement #Taiwan #Taipei #HER2 #EirGenix #EG1206A

EirGenix Strengthens Biosimilar Portfolio with New Licensing Agreement for EG1206A EirGenix Inc. has announced a global licensing agreement with Sandoz for its HER2 biosimilar EG1206A, enhancing cancer treatment options and supporting global access.

EirGenix Strengthens Biosimilar Portfolio with New Licensing Agreement for EG1206A #Taiwan #Taipei #Sandoz #EirGenix #EG1206A

EirGenix Secures Second Global Licensing Deal for HER2 Biosimilar EG1206A EirGenix Inc. has announced a significant global licensing agreement with Sandoz for its HER2 biosimilar EG1206A, enhancing treatment for breast cancer patients.

EirGenix Secures Second Global Licensing Deal for HER2 Biosimilar EG1206A #Taiwan #Taipei #Sandoz #EirGenix #EG1206A